Results 1 to 10 of about 271,757 (165)

Construction of enterovirus G expressing reporter genes for antiviral drug screening assays [PDF]

BMC Veterinary Research
The emergence of Enterovirus G strains harboring recombinant papain-like protease (EV-G-PLP) poses a significant threat to the global swine health with zoonotic potential.
Kaige Chen, Dalin Hong, Lingyou Zeng, Jinni Bian, Shiting Huang, Yifeng Qin, Yeshi Yin, Weijian Huang, Ying Chen, Zuzhang Wei, Kang Ouyang   +10 more
doaj   +2 more sources

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

Journal of Hematology & Oncology, 2017
Background Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Deepika Kanojia, Manoj Garg, Jacqueline Martinez, Anand M.T., Samuel B. Luty, Ngan B. Doan, Jonathan W. Said, Charles Forscher, Jeffrey W. Tyner, H. Phillip Koeffler   +9 more
doaj   +2 more sources

Validation of a modified fluorimetric assay for the screening of trichomonacidal drugs [PDF]

Memorias do Instituto Oswaldo Cruz, 2012
A fluorimetric microassay that uses a redox dye to determine the viability of the flagellate Trichomonas vaginalis has been optimised to provide a more sensitive method to evaluate potential trichomonacidal compounds.
Alexandra Ibáñez Escribano, Alfredo Meneses Marcel, Yanetsy Machado Tugores, Juan José Nogal Ruiz, Vicente J Arán Redó, José Antonio Escario García-Trevijano, Alicia Gómez Barrio   +6 more
doaj   +3 more sources

A Dual-Reporter Fluorescence–Luminescence Assay for Drug Screening in Promastigote and Intracellular Amastigote Stages of Leishmania [PDF]

Molecules
Leishmaniasis is a Neglected Tropical Disease caused by protozoa of the Leishmania genus. No human vaccine is available, and current treatments are limited by toxicity and drug resistance.
Sarah D’Alessandro, Silvia Parapini, Estefanía Calvo-Alvarez, Federica Perego, Gaia Mazza, Abirla Murugan, Nicoletta Basilico   +6 more
doaj   +2 more sources

RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays

Molecules, 2021
RNA splicing is an essential step in producing mature messenger RNA (mRNA) and other RNA species. Harnessing RNA splicing modifiers as a new pharmacological modality is promising for the treatment of diseases caused by aberrant splicing.
Zhichao Tang, Junxing Zhao, Zach J. Pearson, Zarko V. Boskovic, Jingxin Wang   +4 more
doaj   +1 more source

Docking-Based Virtual Screening Enables Prioritizing Protein Kinase Inhibitors With In Vitro Phenotypic Activity Against Schistosoma mansoni

Frontiers in Cellular and Infection Microbiology, 2022
Schistosomiasis is a parasitic neglected disease with praziquantel (PZQ) utilized as the main drug for treatment, despite its low effectiveness against early stages of the worm. To aid in the search for new drugs to tackle schistosomiasis, computer-aided
Bernardo Pereira Moreira, Izabella Cristina Andrade Batista, Naiara Clemente Tavares, Tom Armstrong, Sandra Grossi Gava, Gabriella Parreiras Torres, Marina Moraes Mourão, Franco H. Falcone   +7 more
doaj   +1 more source

Probes and techniques used in active and the hypoxia-based dormant state of an antitubercular drug screening assay

Medicine in Drug Discovery, 2022
Current antitubercular drug therapy requires more than six months and is unable to kill latent or dormant forms of tuberculosis. Thus, it is a need of new drug therapy to fight against dormant tuberculosis.
Amar Yeware, Shamim Akhtar, Dhiman Sarkar   +2 more
doaj   +1 more source

Characterization of glioblastoma spheroid models for drug screening and phototherapy assays

OpenNano, 2023
Glioblastoma (GBM) spheroids present as a promising alternative testing platform for in vivo models of brain cancer, aiming at the 3Rs principle of animal use in pre-clinical trials. However, the poor characterization and irreproducibility of various GBM-
Samara Rodrigues Alves, Italo Rodrigo Calori, Hong Bi, Antonio Claudio Tedesco   +3 more
doaj   +1 more source

Advances in high‐throughput mass spectrometry in drug discovery

EMBO Molecular Medicine, 2022
High‐throughput (HT) screening drug discovery, during which thousands or millions of compounds are screened, remains the key methodology for identifying active chemical matter in early drug discovery pipelines.
Maria Emilia Dueñas, Rachel E Peltier‐Heap, Melanie Leveridge, Roland S Annan, Frank H Büttner, Matthias Trost   +5 more
doaj   +1 more source

Cutting edge strategies for screening of novel anti-HIV drug candidates against HIV infection: A concise overview of cell based assays

Heliyon, 2023
The advent of Highly Active Antiretroviral Therapy has majorly contributed towards reducing the morbidity and mortality associated with HIV infected people, thus improving the quality of their life.
Shraddha Y. Gaikwad, Pallavi Phatak, Anupam Mukherjee   +2 more
doaj   +1 more source